Latest terms of Sesen Bio and Carisma merger appear to pass muster

15 February 2023
sesen_bio_large

Sesen Bio (Nasdaq: SESN) and Carisma Therapeutics have further changed their previously amended merger agreement following investor pushback.

The latest changes appear to satisfy a group of disgruntled shareholders, led by Bradley Radoff and Michael Torok, which together owns around 8.7% of the company.

This time the one-time special cash dividend expected to be paid to Sesen Bio stockholders has been increased to $75 million, a rise of $5 million on the amended amount and of $50 million on the original proposal.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology